Clinical Trials | December 19, 2025
Gilead’s new HIV therapy shows promising Phase 3 results
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
The inspection concluded with one minor observation in Form 483
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Akero became a wholly owned subsidiary of Novo Nordisk
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Subscribe To Our Newsletter & Stay Updated
